September 29, 2023 News by Andrea Lobo, PhD Tiziana seeks sites to conduct Phase 2a trial of nasal foralumab Tiziana Life Sciences has started to recruit clinical sites for a Phase 2a clinical trial that will investigate its foralumab nasal spray in people with nonactive secondary progressive multiple sclerosis (SPMS). The announcement follows a meeting with the principal investigators of the trial at Brigham and Womenās…
June 8, 2023 News by Lindsey Shapiro, PhD Microglial activation reduced in 5 of 6 SPMS patients on nasal foralumab Reductions in microglial activation have been observed in the brains of five of six patients with nonactive secondary progressive multiple sclerosis (SPMS) who received treatment with Tiziana Life Science’s foralumab nasal spray. Microglia, resident immune cells in the brain, are believed to play a role in driving inflammation…
January 4, 2023 News by Lindsey Shapiro, PhD EDSS Score Drop of 1 Point Seen in 2nd SPMS Patient on Foralumab A second person with non-active secondary progressive multiple sclerosis (SPMS) treated with foralumab nasal spray in a single-patient access program is continuing to show improvements 11 months after starting the therapy, according to an update from foralumab’s developer, Tiziana Life Sciences. The patient, dubbed EA2, experienced a…
December 16, 2022 News by Marisa Wexler, MS Foralumab Nasal Spray for MS Well-tolerated in Mice for 3 Months Foralumab, a nasal spray therapy that Tiziana Life Sciences is developing for multiple sclerosis (MS) and other disorders, was well-tolerated in mice for more than three months, according to data from a preclinical study. Tiziana is planning to share that data in a meeting with the U.S. Food…
November 11, 2022 News by Lindsey Shapiro, PhD Tiziana Planning 2023 Launch of Phase 2 Foralumab Trial in SPMS Tiziana Life Sciences plans to request a meeting with the U.S. Food and Drug Administration (FDA) later this year to discuss the upcoming Phase 2 clinical trial of foralumab nasal spray in people with nonactive secondary progressive multiple sclerosis (SPMS). FDA feedback on the design of the…
November 8, 2022 News by Margarida Maia, PhD Expanded Access Program of Nasal Foralumab Enrolls 4 SPMS Patients A group of four patients have entered a special program where theyāll gain access to foralumab nasal spray, an experimental therapy thatās being tested for non-active secondary progressive multiple sclerosis (SPMS). This is the first group of four who entered Tiziana Life Sciencesā intermediate-size expanded access program.
September 21, 2022 News by Lindsey Shapiro, PhD Second SPMS Patient Given Foralumab Continues to Improve Six months of treatment with foralumab nasal spray led to significant functional improvements in the second patient with non-active secondary progressive multiple sclerosis (SPMS) who received treatment under a single-patient expanded access program. Findings from this patient have been generally consistent with those seen in the first non-active SPMS…
June 20, 2022 Columns by Ed Tobias MS News That Caught My Eye Last Week: Vidofludimus Calcium, Foralumab, Exoskeleton, Dysport Vidofludimus Calcium Safely Reduced RRMS Brain Lesions Vidofludimus calcium, also called IMU-838, is an oral therapy designed to reduce the activity of B- and T-cells. These are immune cells believed to be responsible for the inflammation that results in MS damage. In this small study, active lesions ā including…
April 18, 2022 Columns by Ed Tobias MS News That Caught My Eye Last Week: Deep Brain Stimulation, IMCY-0141, Foralumab, Vumerity Select Brain Stimulation May Ease MS Tremor, But More Study Needed This is encouraging news for the large group of people with MS who are bothered by some sort of tremor. But the procedure to suppress these tremors isn’t simple. We’re talking about deep brain stimulation, where electrodes are…
April 12, 2022 News by Marta Figueiredo, PhD 8 More SPMS Patients Cleared for Foralumab Nasal Spray Treatment Based on findings from the first two secondary progressive multiple sclerosis (SPMS) patients givenĀ foralumab nasal spray, an experimental therapy, the U.S. Food and Drug Administration (FDA) has approved starting treatment in up to eight other patients under a special access program. Those enrolled in this intermediate-size expanded access…
March 21, 2022 Columns by Ed Tobias MS News That Caught My Eye Last Week: SPMS Transition, NVG-291, PIPE-307, Foralumab MS Doctors, Nurses in UK Struggle With Marking Transition to SPMS The issue highlighted in this story isn’t just a problem in the U.K.; it’s a universal MS problem. People with MS often ask how they will know when their illness has transitioned from relapsing to progressive. I respond…
March 15, 2022 News by Marta Figueiredo, PhD Foralumab as Nasal Spray Safely, Effectively Treats 1st SPMS Patient Six months of treatment with foralumab, anĀ experimental nasal spray, safely and effectively improved motor and cognitive function while easing immune activation and inflammatory responses in a person with secondary progressive multiple sclerosisĀ (SPMS), Tiziana Life Sciences, the therapyās developer, announced. The patient ā the first with MS to…
June 1, 2021 News by Forest Ray PhD Nasal Foralumab Led to Promising Immune Effects in Phase 1 Trial Nasally-administered foralumab, a potential treatment for neurodegenerative disorders such as progressive forms of multiple sclerosis (MS), appears safe and well-tolerated, and shows immune-modulating and anti-inflammatory effects in healthy volunteers, an updated analysis from a Phase 1 trial has found. āNasal administration of Foralumab is a unique approach to treat…
May 26, 2021 News by Forest Ray PhD First SPMS Patient Dosed With Foralumab Nasal Spray Foralumab, an investigational anti-CD3 antibody that is administered via a nasal spray, has been given for the first time to a person with secondary progressive multiple sclerosis (SPMS). It was administered under an Individual Patient Expanded Access Program, which earnedĀ approval from the U.S. Food and Drug Administration in…
April 1, 2021 News by Margarida Maia, PhD SPMS Patient First To Be Treated With Antibody Given via Nasal Spray For a first time, an immune-modulating antibody will be given via nasal administration to treat a person with secondary progressive multiple sclerosis (SPMS). The U.S. Food and Drug Administration (FDA) approved a request to use the antibody ā a fully human anti-CD3 monoclonal antibody called foralumab ā under an…
January 15, 2016 News by Patricia Silva, PhD Potential MS Treatment Targeting CD3 Receptor Moving into Development Tiziana Life Sciences, plc, a biotechnology company specializing inĀ drugs to treat immunological and oncological diseases,Ā recently announced its intentĀ toĀ further develop foralumab, a fully human monoclonal antibody targeting the CD3 receptor. This approach, aimingĀ to modulate the immune T cell response and achieve immunosuppression, is well-validated and has the potential to…